Seqirus has debuted its first commercial for Fluad, in an early flu season campaign targeting the 65-plus crowd.

The Big Pharma workforce in 2007 appears remarkably similar to the present. Underneath those numbers, though, are some major shifts.

Shire CFO Jeff Poulton’s decision to depart rattled the market Monday, triggering some damage-control efforts by Poulton himself.

Teva is working to sell off its women’s health unit to churn up cash and pay down debt, and it may have some takers.

J&J has objected to Florida using a drug in an execution that was developed by its Janssen unit, saying it doesn't condone its use for capital…

Hikma's U.S. unit West-Ward boosted prices as much as fourfold on a half-dozen generic meds, most of them liquid formulations.

Growing the gout market has been slow going for Ironwood. But now, the company has a new catalyst.

With another win, Bayer and Johnson & Johnson are now three for three in fending off lawsuits over the bleeding risks of blockbuster Xarelto.

One cancer patient is urging Novartis to weigh taxpayer investment in early-stage CAR-T science in setting a price on its new med tisagenlecleucel.